Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice

Hee-Jeong Choi1†, Jin-Hee Park1,2†, Yoo Joo Jeong1, Jeong-Woo Hwang1, Soojung Lee3, Heeyong Lee3, Eunyoung Seol3, Ik-whi Kim4, Byung-Yoon Cha4, Jinsoo Seo2, Minho Moon5* and Hyang-Sook Hoe1,2*

Abstract
The cholinesterase inhibitor donepezil is used to improve Aβ pathology and cognitive function in patients with Alzheimer’s disease (AD). However, the impact of donepezil on tau pathology is unclear. Thus, we examined the effects of donepezil on Aβ and tau pathology in 5xFAD mice (a model of AD) in this study. We found that intraperitoneal injection of donepezil (1 mg/kg, i.p.) exhibited significant reductions in Aβ plaque number in the cortex and hippocampal DG region. In addition, donepezil treatment (1 mg/kg, i.p.) reduced Aβ-mediated microglial and, to a lesser extent, astrocytic activation in 5xFAD mice. However, neither intraperitoneal/oral injection of donepezil nor oral injection of rivastigmine altered tau phosphorylation at Thr212/Ser214 (AT100), Thr396, and Thr231 in 5xFAD mice. Surprisingly, we observed that intraperitoneal/oral injection of donepezil treatment significantly increased tau phosphorylation at Thr212 in 5xFAD mice. Taken together, these data suggest that intraperitoneal injection of donepezil suppresses Aβ pathology but not tau pathology in 5xFAD mice.

Keywords: Alzheimer’s disease, Tau, Tau kinase, Amyloid beta, 5xFAD mice, Donepezil

Alzheimer’s disease (AD) is a neurodegenerative disease that reduces neurocognitive ability [1]. The two neuropathological symptoms of AD are amyloid-β (Aβ) and tau deposition, which are consequently major targets for the development of AD treatments [2]. Unfortunately, most drugs targeting Aβ or tau (single target) have failed in clinical studies [3, 4]. Currently used AD treatments include the acetylcholinesterase inhibitor donepezil, which regulates learning/memory, neuroinflammation, and Aβ pathology in AD patients [5–7], but the impact of donepezil on tau phosphorylation has received limited attention.

To address this gap, we examined the effects of donepezil on Aβ pathology in 5xFAD mice, a model of AD. For these experiments, 5xFAD mice were intraperitoneally (i.p.) injected with vehicle or donepezil (1 mg/kg, i.p.) daily for 2 weeks, followed by immunofluorescence staining with an anti-6E10 antibody. We found that 5xFAD mice treated with donepezil exhibited significant decreases in Aβ plaque number (Fig. 1A–E). In addition, Aβ-mediated microglial activation and, to a lesser extent, astrocyte activation were significantly reduced in donepezil-treated 5xFAD mice (Fig. 1A–D, F–G). These data suggest that intraperitoneal injection of donepezil affects Aβ plaque number and Aβ-stimulated glial activation in 5xFAD mice.

Next, we investigated the impact of oral injection of donepezil on Aβ pathology. For this experiment, 5xFAD mice were orally injected with vehicle or donepezil (3 mg/kg, p.o.) daily for 2 weeks. In addition, wild-type mice were orally injected with vehicle daily for 2 weeks. We found that oral administration of donepezil did not...
significantly alter Aβ plaque number and Aβ-mediated microglial activation in 5xFAD mice (Additional file 1: Fig. S1). However, oral administration of donepezil significantly reduced Aβ-mediated astrocyte activation in the CA1 region (Additional file 1: Fig. S1). Based on our observations and the literature, it is possible that long-term oral injection of donepezil (daily for 3 or 5 months) would affect Aβ pathology in 5xFAD mice. A future study will address this possibility.

We then examined the effects of donepezil on tau pathology in 5xFAD mice. Consistent with previous findings, tau phosphorylation was higher in vehicle-treated 5xFAD mice than in vehicle-treated wild-type mice [8]. Moreover, neither intraperitoneal nor oral injection of donepezil altered tau phosphorylation at Thr212/Ser214, Thr231, or Thr231 in total tau levels compared with vehicle-treated 5xFAD mice (Fig. 1 H-P, Additional file 1: Figs. S2, S3). Surprisingly, we found that tau phosphorylation at Thr212 was significantly enhanced by donepezil treatment Additional file 1: Figs. S2, S3). These data indicate that donepezil has a negative or no impact on tau phosphorylation in 5xFAD mice, depending on the phosphorylation site. We subsequently explored the molecular mechanism by which donepezil affects tau pathology and found that intraperitoneal administration of donepezil significantly upregulated tau kinase p-Cdk5 levels in 5x FAD mice (Fig. 1Q-R).

To test whether other acetylcholinesterase inhibitors can modulate tau phosphorylation in a mouse model of AD, 5xFAD mice were orally injected with rivastigmine (2 mg/kg, p.o.) or vehicle daily for 2 weeks. We found that oral administration of rivastigmine did not alter tau phosphorylation at Thr212/Ser214, Thr231, or Thr396 in 5xFAD mice (Additional file 1: Fig. S4). In summary, intraperitoneal administration of donepezil (1 mg/kg, daily for 2 weeks, i.p.) significantly reduced Aβ plaque number and Aβ-stimulated gliarial activation in 5xFAD mice. However, neither intraperitoneal nor oral injection of donepezil nor oral injection of rivastigmine positively affected tau phosphorylation in 5xFAD mice. Taken together, these data suggest that intraperitoneal injection of donepezil downregulates Aβ pathology and that neither intraperitoneal nor oral administration of donepezil alters tau phosphorylation in 5xFAD mice.

As mentioned above, we and others have found that donepezil improves learning, memory, Aβ pathology, and neuroinflammation in mouse models of AD [5, 7, 9], but studies of the effects of donepezil on tau pathology are scarce. Interestingly, a previous study demonstrated that injection of tau-overexpressing PS19 mice with donepezil (8 month injection period) significantly reduced tau phosphorylation at Ser202/Thr205 [10]. Another study found that donepezil treatment (1.3 mg/kg, intragastrically once daily) did not alter tau phosphorylation at Ser202, Ser396, or Ser416 [11]. These conflicting findings on the effects of donepezil on tau pathology may be due to differences in AD mouse models (tau-overexpressing PS19 mice vs. APP/PS1 and APP/PS1/Tau Tg mice), donepezil administration methods/durations, and donepezil dosages. In the present study, we assessed tau pathology in 3- to 4-month-old Aβ-overexpressing 5xFAD mice or wild-type mice that were injected with donepezil or vehicle daily for 2 weeks. The wild-type mice expressed basal levels of tau phosphorylation, consistent with previous findings [11]. In 5xFAD mice, most sites of tau phosphorylation (Thr212/Ser214, Thr231, and Thr396) were unaffected by donepezil or rivastigmine treatment (Fig. 1, Additional file 1: Figs. S3, S4). Based on the literature and our findings, it is possible that long-term injection or lower/higher doses (e.g., 0.7 or 1.3 mg/kg) of donepezil or rivastigmine might have different effects on tau pathology in 5xFAD mice, which will be examined in future work.

In addition, intraperitoneal injection of donepezil significantly increased tau phosphorylation at Thr212 and tau kinase p-Cdk5 levels (Fig. 1Q-R, Additional file 1: Fig. S2). It is possible that the increase in tau phosphorylation at Thr212 was due to activation of the tau kinase p-Cdk5. Another possibility is that donepezil modulated another tau kinase (e.g., DYRK1A or p-GSK3β) to directly and/or indirectly affect tau phosphorylation. We will evaluate the effects of donepezil on the activation of other tau kinases and tau pathology in young and old 5xFAD mice (3 and 8 months old) in a future study.

In conclusion, intraperitoneal injection of donepezil daily for 2 weeks suppressed Aβ plaque levels and Aβ-stimulated glial activation in 5xFAD mice. Oral or intraperitoneal injection of donepezil or oral injection of rivastigmine daily for 2 weeks did not positively affect tau phosphorylation in 5xFAD mice. Taken together, our
findings suggest that intraperitoneal administration of donepezil inhibits Aβ pathology and that neither intraperitoneal/oral administration of donepezil nor oral administration of rivastigmine regulates tau pathology in 5xFAD mice.

Abbreviations
Aβ: Amyloid β; AD: Alzheimer’s disease; Cdk-5: Cyclin-dependent kinase 5; DG: Dentate gyrus; GSK-3β: Glycogen synthase kinase-3β.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13041-022-00948-1.

Additional file 1: Fig. S1. Oral injection of 3 mg/kg donepezil does not affect Aβ plaque number in 5xFAD mice. Fig. S2. Intraperitoneal administration of donepezil does not alter total tau levels but significantly increases tau phosphorylation at Thr212 in 5xFAD mice. Fig. S3. Oral injection of 3 mg/kg donepezil does not alter tau phosphorylation at Thr212/Ser214 and Thr396 but significantly increases tau phosphorylation at Thr212 in 5xFAD mice. Fig. S4. Oral injection of rivastigmine does not affect tau phosphorylation in 5xFAD mice. Additional Materials and Methods section.

Acknowledgements
Confocal microscopy (Nikon, Ti-RCP) data were acquired at the Advanced Neural Imaging Center at the Korea Brain Research Institute (KBRI). We thank previous and current members of the neurodegenerative diseases lab for editing and valuable comments on our manuscript and for technical assistance with in vitro work and in vivo studies.

Author contributions
MM, SJ, HL, ES, IWK, BYC, JS, and HSH conceived and participated in the design of the study. HJC, JHP, JWH, and YJJ performed in vivo experiments and histological analysis. HJC, MM, and HSH wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the KBRI basic research program through KBRI funded by the Ministry of Science, ICT & Future Planning (Grant Numbers 22-BR-02-03, 22-BR-03-05, 22-BR-04-01, H.S.H.) and the National Research Foundation of Korea (Grant number 2019R1A2B5B01070108).

Availability of data and materials
All data generated and/or analyzed during this study are included in this published article and its Additional information. Materials and methods are presented in the Additional information.

Declarations

Ethics approval and consent to participate
All animal experiments were approved by the Institutional Animal Care and Use Committee at the Korea Brain Research Institute (KBRI) (Assigned No. IACUC-2016-0013, IACUC-19-00049, IACUC-19-00042).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Neural Development and Disease, Korea Brain Research Institute (KBRI), 61, Cheomdan-ro, Dong-gu, 41068 Daegu, Republic of Korea. 2 Department of Brain Sciences, Daegu Gyeongbuk Institute of Science & Technology, 42988 Daegu, Korea. *G2GBIO, Inc., Science Park#411, 1646 Yuseond-daero, Yuseong-gu, 34054 Daejeon, Korea. †PharmacoRex Co., Ltd., 20 Techno 1-ro, Yuseong-gu, 34016 Daejeon, Korea. ‡Department of Biochemistry, College of Medicine, Konyang University, 35365 Daejeon, Korea.

Received: 30 June 2022 Accepted: 6 July 2022
Published online: 18 July 2022

References
1. Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320.
2. La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, Chaudhary K, Edwards L, Iaccarino L, Janabi M, Lesman-De-Jeuk OH. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732.
3. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):1–3.
4. Zheng H, Fridkin M, Youdim M. From single target to multitarget/network therapeutics in Alzheimer’s therapy. Pharmaceuticals. 2014;7(2):113–35.
5. Guo HB, Cheng YF, Wu JG, Wang CM, Wang HT, Zhang C, Qiu ZK, Xu JP. Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Neuroscience. 2015;290:50–42.
6. Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H, Tang S. S-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease: Brain Behav Immun. 2020;88:844–55.
7. Kim J, Lee HJ, Park SK, Park JH, Jeong HR, Lee S, Lee H, Seol E, Hoe HS. Donepezil regulates LPS and Aβ-stimulated neuroinflammation through MAPK/NLRP3 inflammasome/STAT3 signaling. Int J Mol Sci. 2021;22(19):10637.
8. Huang Q, Li CY, Zhang N, Zhang Q, Li HY, Shen Y, Xie LS, Yu SG, Wu QF. The effects of moxibustion on learning and memory and m6A RNA methylaion in APP/PS1 mice. Evid Based Complementary Altern Med. 2022. https://doi.org/10.1155/2022/2998301.
9. Ongsuk B, Khuanjing T, Chunchai T, Kerdphoo S, Jaiwongkam T, Chatipakorn S, Thamnakorn SC. Donepezil provides neuroprotective effects against brain injury and Alzheimer’s pathology under conditions of cardiac ischemia/reperfusion injury. Biochim Biophys Acta Mol Basis Dis. 2021;1867(1):165975.
10. Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimer’s Dis. 2010;22(1):295–306.
11. Zhang G, Wu J, Huang C, Cheng J, Su Z, Zhu Z, Yang X, Guo B, Wu L, Zhang Z, Zhang G. The tetramethylpyrazine analogue T-006 alleviates cognitive deficits by inhibition of tau expression and phosphorylation in transgenic mice modeling Alzheimer’s disease. J Mol Neurosci. 2021;71(7):1456–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.